EAM
CATX icon

Eagle Asset Management’s Perspective Therapeutics CATX Stock Holding History

Eagle Asset Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.04M Sell
181,467
-60,212
-25% -$801K 0.01% 459
2024
Q2 		$2.71M Buy
+241,679
New +$3.49M 0.01% 445

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Eagle Asset Management's CATX Position: Q3 2024 in Review

Eagle Asset Management reduced its Perspective Therapeutics (CATX) stake by 25% in Q3 2024, selling an estimated $801K and leaving 181,467 shares worth $2.04M. The position accounts for 0.01% of the portfolio, ranked #459.

Eagle Asset Management first reported a position in CATX in Q2 2024 and has held it in 2 quarters since. The position peaked at $2.71M in Q2 2024. 127 funds tracked by Wall St. Rank hold CATX as of Q3 2024.

  • Eagle Asset Management held 181,467 shares of Perspective Therapeutics worth $2.04M as of Q3 2024.
  • Eagle Asset Management sold 60,212 Perspective Therapeutics shares in Q3 2024, an estimated $801K.
  • Perspective Therapeutics made up 0.01% of Eagle Asset Management's portfolio in Q3 2024, its #459 holding.
  • Eagle Asset Management first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Eagle Asset Management's Perspective Therapeutics position peaked at $2.71M in Q2 2024.
  • 127 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.